Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

Author's Avatar
Jan 10, 2023

Pear+Therapeutics%2C+Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with COEUS+HealthCare%2C+LLC (“COEUS”), a leading life sciences technology and consulting firm, to utilize its outcomes and evidence-based reimbursement adjudication platform, COEBRA™ to help enable value-based contracting. As Pear continues to engage in clinical and contractual conversations with state Medicaid programs, its agreement with COEUS makes it easier for individual states to engage in value-based contracting to access Pear’s PDTs. Pear's commercial products, reSET® and reSET-O®, are among a limited number of products initially included in the solution and are the only PDTs on the platform.